Opinion|Videos|May 5, 2025
Lp(a) Testing: Prevalence and Strategies to Improve Uptake
Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its commonality within health plans, and how payers, population health decision makers, and provider groups can integrate Lp(a) testing into broader population health management strategies.
Advertisement
Video content above is prompted by the following:
- Currently, how prevalent is Lp(a) testing in the US, both in the overall population and among those with established ASCVD?
- How common is Lp(a) testing within the health plans that you work with?
- How can payers, population health decision makers working at health systems, and provider groups infuse Lp(a) testing into their larger population health management infrastructure?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Paul Richardson, MD, Calls Mezigdomide “CAR T in a Pill” for Patients With R/R Multiple Myeloma
4
Type 5 Diabetes: A Long-Ignored Condition Gets Its Moment
5